UCB (FRA:UNC) EPS (Basic) : €1.26 (TTM As of Jun. 2024)

View and export this data going back to . Start your Free Trial

What is UCB EPS (Basic)?

UCB's basic earnings per share (Basic EPS) for the six months ended in Jun. 2024 was €1.09. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Jun. 2024 was €1.26.

UCB's EPS (Diluted) for the six months ended in Jun. 2024 was €1.06. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €1.22.

UCB's EPS without NRI for the six months ended in Jun. 2024 was €1.07. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Jun. 2024 was 1.21.

During the past 12 months, UCB's average EPS without NRIGrowth Rate was -36.40% per year. During the past 3 years, the average EPS without NRI Growth Rate was -25.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was -27.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 1.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, UCB's highest 3-Year average EPS without NRI Growth Rate was 65.20% per year. The lowest was -34.20% per year. And the median was 3.30% per year.

UCB EPS (Basic) Historical Data

The historical data trend for UCB's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

UCB EPS (Basic) Chart

UCB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EPS (Basic)

Get a 7-Day Free Trial

8.46

3.87

5.60

2.20

1.81

UCB Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
EPS (Basic)	Get a 7-Day Free Trial															2.10	0.10	1.64	0.17	1.09

UCB EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

UCB's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as

Basic EPS (A: Dec. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(343	-	0)	/	189.690
	=	1.81

UCB's Basic EPS for the quarter that ended in Jun. 2024 is calculated as

Basic EPS (Q: Jun. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(208	-	0)	/	189.887
	=	1.10

EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1.26

UCB (FRA:UNC) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

UCB EPS (Basic) Related Terms

Thank you for viewing the detailed overview of UCB's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

UCB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » UCB SA (FRA:UNC) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

UCBJY:USA UCBJF:USA UCBb:UK 0NZT:UK UCB:Belgium UCB:Austria

Address

Allee de la Recherche, 60, Brussels, BEL, B-1070

Website

https://www.ucb.com

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), and Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome).

UCB Headlines

No Headlines